Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a confirmed diagnosis of a B-cell blood cancer (such as diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia), with disease that can be measured on scans and requires treatment.
- People whose blood and organ function test results fall within the ranges required by the trial.
- People who have previously been treated with a therapy that targets a protein called CD19, where a tissue sample (biopsy) from the tumour has been collected after that most recent treatment.
- People whose disease is measurable according to a standard set of guidelines called the 2014 Lugano Classification.
Who may not be able to join:
- People with known active cancer affecting the brain or spinal cord, or a type of lymphoma that starts in the brain or spinal cord (primary CNS lymphoma).
- People with a known active infection or other serious uncontrolled medical conditions as specified by the trial (confirm with trial site).
- People whose general health and ability to carry out daily activities is significantly limited, as measured by a standard scale used by doctors called the ECOG performance status — specifically, those with a score of 2 or higher on that scale (confirm with trial site for details on what this means in practice).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Dose-Limiting Toxicities (DLT); Number of Participants with Adverse Events (AE); Maximum Observed Serum Concentration (Cmax) of ABBV-319; Time to Cmax (Tmax) of ABBV-319; Terminal Phase Elimination Half-Life (t1/2) of ABBV-319; Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-319; Antidrug Antibody (ADA)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.